Previous 10 | Next 10 |
Results from the phase 3 RESPONSE study, which is using Seladelpar for the treatment of patients with primary biliary Cholangitis, are expected in 2023. PBC patients treated with Seladelpar over a 2-year period saw a decrease in GLOBE PBC Score and improved transplant-free survival. ...
Gainers:Scholar Rock Holding (SRRK) +6%. Science 37 Holdings (SNCE) +6%. Arcimoto (FUV) +5%. Hyzon Motors (HYZN) +4%. SoundHound (SOUN) +4%. Losers: Guardant Health (GH) -5%. CymaBay Therapeutics (CBAY) -5%. Polestar Automotive Holding (PSNY) -5%. Adagio Therapeutics, (...
Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival NEWARK, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver a...
NEWARK, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that multiple seladelpar presentations will be d...
Penny stocks can be your greatest asset or worst enemy, depending on how you trade them. Their low prices lend themselves to considerable gain potential, and I’m not just talking 5 or 10%. Almost daily, we see stocks under $5 explode by 50% or more…yes, 50% or more. But with t...
CymaBay Therapeutics (NASDAQ:CBAY) stock edge higher after disclosing that its CEO Sujal Shah bought 51.301K shares of common stock on 6 June. As per regulatory filing, shares were purchased at $1.95, for total transaction size of $100K. For further details see: CymaBay Therapeutic...
Gainers: Mirati Therapeutics (MRTX) +23%. CymaBay Therapeutics (CBAY) +16%. Veru (VERU) +9%. Kodiak Sciences (KOD) +8%. Allarity Therapeutics (ALLR) +7%. Losers: Verastem (VSTM) -12%. Delcath Systems (DCTH) -11%. Vicarious Surgical (RBOT) -8%. CEL-...
CymaBay Therapeutics (NASDAQ:CBAY -4.3%) said on Monday that results from a new analyses of clinical studies showed that seladelpar treatment through two years resulted in a decrease in Primary Biliary Cholangitis globe score and predicted improved transplant-free survival. The comp...
NEWARK, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that results from new analyses of cl...
H.C. Wainwright has trimmed the price target on the clinical-stage biopharma company CymaBay Therapeutics (NASDAQ:CBAY) on Monday, citing a delay in the enrollment for the second global Phase 3 trial for its lead candidate seladelpar in primary biliary cholangitis (PBC). With its 1Q 2022 earn...
News, Short Squeeze, Breakout and More Instantly...
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for appr...
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.06% on the day to $32.49. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chr...
Gilead Sciences Inc’s (NASDAQ:GILD) executive revealed the company’s plans to increase its production of cell therapy cancer treat...